MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
1.070
-0.010
-0.93%
After Hours: 1.050 -0.02 -1.87% 18:54 05/13 EDT
OPEN
1.060
PREV CLOSE
1.080
HIGH
1.100
LOW
1.045
VOLUME
280.74K
TURNOVER
--
52 WEEK HIGH
5.18
52 WEEK LOW
0.3975
MARKET CAP
14.98M
P/E (TTM)
-0.1693
1D
5D
1M
3M
1Y
5Y
1D
Moleculin Biotech Q1 EPS $(0.69) Beats $(0.83) Estimate
Benzinga · 2h ago
Here are the major earnings after the close today
Seeking Alpha · 9h ago
Earnings Scheduled For May 13, 2025
Benzinga · 14h ago
BUZZ-U.S. STOCKS ON THE MOVE-Fox, Manpower Group, US chipmakers
Reuters · 1d ago
BUZZ-Moleculin Biotech rises after EMA approves late-stage study of cancer therapy
Reuters · 1d ago
Moleculin Biotech’s Annamycin Trial Approved by EMA
TipRanks · 1d ago
Moleculin Biotech receives EMA approval to expand Phase 3 MIRACLE trial
TipRanks · 1d ago
Moleculin Biotech Receives EMA Approval For Clinical Trial Application To Conduct Pivotal Phase 2B/3 AnnAraC Clinical Trial
Benzinga · 1d ago
More
About MBRX
More
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Recently
Symbol
Price
%Change

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.